Q-omics provides the consensus-scored TLR5 profile across patient tissues and cancer cell-line models. TLR5 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, TLR5 is differentially expressed in 13, with the highest sampling consensus in KICH. Additionally, TLR5 RNA expression shows 18,637 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight ACC, KICH, and UVM as cancer lineages where TLR5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TLR5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TLR5 survival associations across molecular data types. TLR5 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (6) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TLR5 RNA expression–survival associations across cancer types. High TLR5 expression shows unfavorable associations in LGG, KIRP and LAML, but favorable associations in ACC, SKCM and SARC. The ACC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .002). Together, the overview and detailed table identify ACC as the clearest survival context for TLR5 RNA expression.
This table summarizes TLR5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TLR5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TLR5 shows lower tumor expression in KICH, KIRC, LUAD, COAD and HNSC and higher tumor expression in LIHC. The KICH box plot shows higher TLR5 RNA expression in normal versus tumor tissue (log2 FC = −2.391, t-test p < 0.001).
This table shows molecular features associated with TLR5 in patient tissues and cancer cell lines. In patient samples, TLR5 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, TLR5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE and BONE.
